National Mammography Quality Assurance Advisory Committee; Notice of Meeting, 51918-51919 [2016-18592]
Download as PDF
51918
Federal Register / Vol. 81, No. 151 / Friday, August 5, 2016 / Notices
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Janie Kim at
least 7 days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 1, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special
Medical Programs.
[FR Doc. 2016–18560 Filed 8–4–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Pediatric Master Protocols; Public
Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration (FDA), in collaboration
with the University of Maryland Center
of Excellence in Regulatory Science and
Innovation, is announcing a public
workshop titled, ‘‘Pediatric Master
Protocols’’. The objective of the
workshop is to discuss regulatory and
scientific concerns related to pediatric
master protocols and clinical trial
design considerations for these
protocols. In addition, applications of
pediatric master protocols to specific
pediatric therapeutic areas will be
presented.
SUMMARY:
The public workshop will be
held on September 23, 2016, from 8:30
a.m. to 4:30 p.m.
ADDRESSES: The public workshop will
be held at FDA’s White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993–
0002. Entrance for the public meeting
participants (non-FDA employees) is
through Building 1 where routine
security check procedures will be
mstockstill on DSK3G9T082PROD with NOTICES
DATES:
VerDate Sep<11>2014
17:42 Aug 04, 2016
Jkt 238001
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
FOR FURTHER INFORMATION CONTACT:
Audrey Thomas, Office of Regulatory
Science and Innovation, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4220, Silver Spring,
MD 20993–0002, 301–796–3520,
Audrey.Thomas@fda.hhs.gov.
The
purpose of this public workshop is to
provide an opportunity for relevant
stakeholders including: Clinicians and
scientists from FDA and other
government Agencies, academia, nonprofit organizations, and industry to
discuss use of pediatric master protocols
for development of medical products for
children. Specifically, the workshop
will present the current status of
pediatric protocol development in the
United States, considerations for
pediatric protocol development
internationally, and development of
international consortia in this area.
Clinical trial design considerations and
the preliminary steps needed for
development of pediatric master
protocols, including the role of in vitro
diagnostic tests, will also be discussed.
Finally, examples of pediatric master
protocol development for medical
products with no, partial, and full
extrapolation of data from adults to
children will be presented. The
workshop will include two panel
sessions for interaction and discussion
among the speakers and attendees.
Agenda: The agenda is available at
https://www.fda.gov/ScienceResearch/
SpecialTopics/RegulatoryScience/
ucm507079.htm (FDA has verified the
Web site address, but FDA is not
responsible for subsequent changes to
the Web site after this document
publishes in the Federal Register).
Registration: There is a registration fee
to attend this public workshop inperson. Seats are limited and
registration will be on a first-come, firstserved basis. To register, please
complete registration online at https://
www.fda.gov/ScienceResearch/Special
Topics/RegulatoryScience/
ucm507079.htm (FDA has verified the
Web site address, but FDA is not
responsible for subsequent changes to
the Web site after this document
publishes in the Federal Register).
There will be no onsite registration. The
costs of registration, to attend in-person,
for different categories of attendees are
as follows:
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
Category
Cost
Industry Representative ........
Nonprofit Organization and
Academic Other Than University of Maryland ............
University of Maryland, College Park and Baltimore ...
Federal Government .............
$50
50
0
0
Streaming Webcast of the Public
Workshop: This public workshop will
also be Webcast. There is no registration
fee for access to the workshop via the
Webcast, but registration is still
required. Information regarding
registration and access to the Webcast
link is available at https://www.fda.gov/
ScienceResearch/SpecialTopics/
RegulatoryScience/ucm507079.htm. If
you have never attended a Connect Pro
event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. (FDA has
verified the Web site addresses in this
document, but FDA is not responsible
for any subsequent changes to the Web
sites after this document publishes in
the Federal Register.)
Accommodations: Attendees are
responsible for their own hotel
accommodations. If you need special
accommodations while at FDA’s White
Oak Campus due to a disability, please
contact Shari Solomon at
Shari.Solomon@fda.hhs.gov at least 7
days in advance.
Dated: August 1, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–18555 Filed 8–4–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
National Mammography Quality
Assurance Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the National Mammography
Quality Assurance Advisory Committee.
The general function of the committee is
to provide advice and recommendations
to the Agency on FDA’s regulatory
SUMMARY:
E:\FR\FM\05AUN1.SGM
05AUN1
Federal Register / Vol. 81, No. 151 / Friday, August 5, 2016 / Notices
issues. The meeting will be open to the
public.
DATES: The meeting will be held
Thursday, September 15, 2016, from
8:30 a.m. to 4:30 p.m.
ADDRESSES: Hilton Washington, DC
North/Gaithersburg, Salons A, B, C and
D, 620 Perry Pkwy., Gaithersburg, MD
20877. The hotel’s telephone number is
301–977–8900. Answers to commonly
asked questions including information
regarding special accommodations due
to a disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm408555.htm.
S.J.
Anderson, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1643, Silver Spring,
MD 20993, Sara.Anderson@fda.hhs.gov,
301–796–7047, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
FOR FURTHER INFORMATION CONTACT:
mstockstill on DSK3G9T082PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Agenda: The Committee will discuss
and make recommendations on:
• Compliance Analysis. This
presentation will be focused on
Mammography Quality Standards Act
(MQSA) current compliance trends,
such as how most compliance cases
originate. Input from the committee on
any trends seen in the analysis, why the
trends may be occurring, and possible
actions will be sought.
• Inspection Enhancement Project.
This presentation will describe a
proposal to use the inspection program
to enhance image quality. FDA is
seeking committee input on anticipated
facility questions related to the
proposal.
• The approved alternative standard
American College of Radiology Full
Field Digital Mammography Quality
Control Manual. The manual’s contents
will be explained and FDA will ask the
committee’s advice on facility roll-out
strategies.
VerDate Sep<11>2014
17:42 Aug 04, 2016
Jkt 238001
• Issues related to breast density. A
presentation of current issues followed
by a committee discussion on how these
issues might effect a possible MQSA
requirement for reporting breast density.
• Future challenges for MQSA, such
as the role of synthesized 2D images.
FDA is seeking committee input on this
challenge as well as what future
challenges MQSA might encounter.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before September 7, 2016.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before August
30, 2016. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 31, 2016.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Artair Mallett
at 301 796–9638 at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
51919
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 1, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special
Medical Programs.
[FR Doc. 2016–18592 Filed 8–4–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health
Resources and Services Administration
(HRSA) has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period.
DATES: Comments on this ICR should be
received no later than September 6,
2016.
SUMMARY:
Submit your comments,
including the ICR title, to the desk
officer for HRSA, either by email to
OIRA_submission@omb.eop.gov or by
fax to 202–395–5806.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email the
HRSA Information Collection Clearance
Officer at paperwork@hrsa.gov or call
(301) 443–1984.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
The Teaching Health Center Graduate
Medical Education (THCGME) Program
Eligible Resident/Fellow FTE Chart.
OMB No. 0915–0367—Revision.
Abstract: The Teaching Health Center
Graduate Medical Education (THCGME)
Program, section 340H of the Public
ADDRESSES:
E:\FR\FM\05AUN1.SGM
05AUN1
Agencies
[Federal Register Volume 81, Number 151 (Friday, August 5, 2016)]
[Notices]
[Pages 51918-51919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18592]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0001]
National Mammography Quality Assurance Advisory Committee; Notice
of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the National Mammography Quality
Assurance Advisory Committee. The general function of the committee is
to provide advice and recommendations to the Agency on FDA's regulatory
[[Page 51919]]
issues. The meeting will be open to the public.
DATES: The meeting will be held Thursday, September 15, 2016, from 8:30
a.m. to 4:30 p.m.
ADDRESSES: Hilton Washington, DC North/Gaithersburg, Salons A, B, C and
D, 620 Perry Pkwy., Gaithersburg, MD 20877. The hotel's telephone
number is 301-977-8900. Answers to commonly asked questions including
information regarding special accommodations due to a disability,
visitor parking, and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT: S.J. Anderson, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1643, Silver Spring, MD 20993,
Sara.Anderson@fda.hhs.gov, 301-796-7047, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). A notice in the Federal Register about last minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The Committee will discuss and make recommendations on:
Compliance Analysis. This presentation will be focused on
Mammography Quality Standards Act (MQSA) current compliance trends,
such as how most compliance cases originate. Input from the committee
on any trends seen in the analysis, why the trends may be occurring,
and possible actions will be sought.
Inspection Enhancement Project. This presentation will
describe a proposal to use the inspection program to enhance image
quality. FDA is seeking committee input on anticipated facility
questions related to the proposal.
The approved alternative standard American College of
Radiology Full Field Digital Mammography Quality Control Manual. The
manual's contents will be explained and FDA will ask the committee's
advice on facility roll-out strategies.
Issues related to breast density. A presentation of
current issues followed by a committee discussion on how these issues
might effect a possible MQSA requirement for reporting breast density.
Future challenges for MQSA, such as the role of
synthesized 2D images. FDA is seeking committee input on this challenge
as well as what future challenges MQSA might encounter.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
September 7, 2016. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before August 30, 2016. Time allotted for
each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by August 31, 2016.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Artair Mallett at 301 796-9638 at least 7 days in advance of
the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: August 1, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special Medical Programs.
[FR Doc. 2016-18592 Filed 8-4-16; 8:45 am]
BILLING CODE 4164-01-P